Unichem Laboratories
- Market cap
- ₹ 3,280 Cr.
- P/E
- 27.2x
- P/B
- 1.26x
- 52-week range
- 278.2 – 687.2
- ROE
- 3%
- ROCE
- 4%
- Dividend yield
- 0%
- Debt / equity
- 0.18
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Unichem Laboratories Limited is an India-based international, integrated, specialty pharmaceutical company. The Company is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. It manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. It has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The Company is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Unichem Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)27.2 against a typical 34: cheaper than most peers (1st = cheapest).92nd of 220
- Sales growth+20.1% against a typical +15.6% from a year earlier.80th of 197
- Share price, 3 months−8.1% against a typical −0.5%.138th of 200
- Size₹ 3,280.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).63rd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A+ | Stable | 9 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 9 Apr 2026 | Reaffirmed | [ICRA]A+ | — | ICRA | ₹ 180 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 4 Nov 2026Upcoming | Financial Results | To consider and approve the unaudited financial results for the period ended September 30, 2026 |
| 11 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 5 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 4 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 22 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
| 6 Feb 2025 | Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 416 | 466 | 432 | 483 | 507 | 533 | 587 | 527 | 579 | 521 | 575 | 633 |
| Expenses | 407 | 435 | 406 | 443 | 452 | 448 | 503 | 504 | 513 | 476 | 527 | 563 |
| Operating Profit | 9 | 31 | 25 | 40 | 55 | 86 | 84 | 22 | 66 | 45 | 48 | 70 |
| OPM % | 2.1% | 7% | 6% | 8% | 11% | 16% | 14% | 4.3% | 11% | 9% | 8% | 11% |
| Other Income | 6 | 79 | −119 | 4 | 9 | 14 | 9 | 7 | −37 | 287 | 11 | 16 |
| Interest | 7 | 6 | 5 | 4 | 5 | 7 | 5 | 7 | 8 | 7 | 9 | 7 |
| Depreciation | 29 | 32 | 27 | 32 | 32 | 31 | 30 | 32 | 31 | 31 | 31 | 30 |
| Profit before tax | −22 | 73 | −126 | 8 | 27 | 62 | 58 | −9 | −11 | 293 | 19 | 49 |
| Tax % | 12% | 0% | 3% | 74% | 9% | 6% | 8% | 16% | 10% | 10% | 42% | 15% |
| Net Profit | −24 | 73 | −129 | 2 | 25 | 58 | 53 | −10 | −12 | 264 | 11 | 41 |
| EPS in Rs | −3.48 | 10.4 | −18.37 | 0.29 | 3.5 | 8.22 | 7.52 | −1.49 | −1.69 | 37.54 | 1.55 | 5.89 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 5%
- 5 Years
- 12%
- 3 Years
- 18%
- TTM
- 7%
- 10 Years
- −3%
- 5 Years
- 25%
- 3 Years
- 35%
- TTM
- −2%
- 10 Years
- 7%
- 5 Years
- 14%
- 3 Years
- 9%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 0%
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Unichem Laboratories | ₹ 490.00 | ₹ 3,280 Cr. | 27.2x | 1.3x | 3% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.1x | 2.4x | 9.9% | 10.4% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 64.3x | 12.6x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.5x | 5x | 17.2% | 28.7% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.3x | 5.4x | 16.7% | 15% |
| Themis Medicare | ₹ 90.00 | ₹ 826 Cr. | 632.2x | 2.5x | 0.3% | 0.3% |
Management
- Sanjay Jain
- Chief Financial Officer
- Pradeep Bhandari
- Compliance Officer, Company Secretary and Head Legal
- Pabitrakumar Kalipada Bhattacharyya
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.